



F. No. 01-02/2025-CPS(DRAP)
Government of Pakistan
Ministry of National Health Services, Regulation & Coordination
Drug Regulatory Authority of Pakistan
Prime Minister Health Complex, Park Road, Islamabad


Islamabad, the 27th May 2025.

NOTIFICATION

Subject: **PRIORITY PROCESSING OF MEXILETINE REGISTRATION APPLICATIONS**

In light of the current non-registration status of Mexiletine and to ensure its earliest possible availability, the Drug Regulatory Authority of Pakistan (DRAP) has designated Mexiletine as priority drug. All registration applications for Mexiletine will be processed on a priority basis, out of queue, for a period of six (6) months from the date of this notification.

2. All relevant stakeholders are requested to acknowledge this decision of DRAP and proceed accordingly to facilitate the expedited processing and availability of Mexiletine in the market.


(Ahsan Ul Haq Athar)

Deputy Director

Communication, Publication & Stakeholder Engagement
CEO-Secretariate

Distribution: -

1. PS to CEO-DRAP, Islamabad
2. Director (PE&R), DRAP, Islamabad.
3. Director (MIS), DRAP with request to upload on DRAP official website.
4. Chairman, Pakistan Pharmaceutical Manufacturer Association (PPMA), H.No.474, St.34 I-8/2 Islamabad
5. Executive Director, Pharma Bureau, Chamber of Commerce, Talpur Road, Karachi.
6. Pakistan Chemist and Druggist Association (PCDA), Suit No.504, 5th Floor, Mashriq Center, Block 14, Gulshan e Iqbal, Karachi.
7. Office File